<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:arxiv="http://arxiv.org/schemas/atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title>stat.OT updates on arXiv.org</title>
    <link>http://rss.arxiv.org/rss/stat.OT</link>
    <description>stat.OT updates on the arXiv.org e-print archive.</description>
    <atom:link href="http://rss.arxiv.org/rss/stat.OT" rel="self" type="application/rss+xml"/>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <language>en-us</language>
    <lastBuildDate>Fri, 04 Jul 2025 04:23:28 +0000</lastBuildDate>
    <managingEditor>rss-help@arxiv.org</managingEditor>
    <pubDate>Fri, 04 Jul 2025 00:00:00 -0400</pubDate>
    <skipDays>
      <day>Saturday</day>
      <day>Sunday</day>
    </skipDays>
    <item>
      <title>BACTA-GPT: An AI-Based Bayesian Adaptive Clinical Trial Architect</title>
      <link>https://arxiv.org/abs/2507.02130</link>
      <description>arXiv:2507.02130v1 Announce Type: cross 
Abstract: Bayesian adaptive clinical trials offer a flexible and efficient alternative to traditional fixed-design trials, but their implementation is often hindered by the complexity of Bayesian computations and the need for advanced statistical programming expertise. The authors introduce a custom fine-tuned LLM designed to assist with this and lower barriers to adoption of Bayesian methods for adaptive clinical trials. This paper describes the development and fine-tuning of BACTA-GPT, a Large Language Model (LLM)-based tool designed to assist in the implementation of Bayesian Adaptive Clinical Trials. This engine uses GPT-3.5 as the underlying model and takes in Natural Language input from the Statistician or the Trialist. The fine-tuned model demonstrates a viable proof-of-concept in its objectives. Test case evaluations show that the model is capable of generating a fit-for-purpose Bayesian model for an adaptive trial and evaluate its operating characteristics via simulations using R and JAGS. The integration of AI code generation has significant potential to lower technical barriers for the design and implementation of Bayesian Adaptive trials. But they also require attention to important considerations regarding validation and quality control.</description>
      <guid isPermaLink="false">oai:arXiv.org:2507.02130v1</guid>
      <category>stat.AP</category>
      <category>stat.OT</category>
      <pubDate>Fri, 04 Jul 2025 00:00:00 -0400</pubDate>
      <arxiv:announce_type>cross</arxiv:announce_type>
      <dc:rights>http://arxiv.org/licenses/nonexclusive-distrib/1.0/</dc:rights>
      <dc:creator>Krishna Padmanabhan, Danny Baker</dc:creator>
    </item>
  </channel>
</rss>
